Hims & Hers Health, Inc. $HIMS Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 4.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,518,015 shares of the company’s stock after purchasing an additional 844,991 shares during the period. Vanguard Group Inc. owned approximately 8.64% of Hims & Hers Health worth $1,107,062,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Invesco Ltd. boosted its position in Hims & Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after buying an additional 2,128,587 shares during the last quarter. Clear Street LLC purchased a new position in Hims & Hers Health during the 2nd quarter worth approximately $83,582,000. Norges Bank acquired a new stake in Hims & Hers Health during the 2nd quarter valued at approximately $78,464,000. Marex Group plc acquired a new stake in Hims & Hers Health during the 2nd quarter valued at approximately $53,626,000. Finally, State of Michigan Retirement System boosted its holdings in shares of Hims & Hers Health by 49.2% in the 3rd quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after acquiring an additional 678,600 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several recent research reports. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Barclays started coverage on Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target on the stock. Zacks Research cut Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. Deutsche Bank Aktiengesellschaft set a $31.00 target price on Hims & Hers Health and gave the stock a “hold” rating in a research note on Tuesday, February 10th. Finally, Bank of America dropped their target price on Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $39.32.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Acquisition expands international footprint and revenue run‑rate — Hims & Hers agreed to buy Australian digital‑health provider Eucalyptus in a deal worth up to $1.15 billion, a move management says will accelerate global growth and add a high‑growth revenue stream. Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion
• Positive Sentiment: Deal expected to materially increase top line and international scale — Coverage notes Eucalyptus brings ~ $450M of annual revenue growing at triple‑digit rates and should accelerate HIMS’ personalized care footprint outside the U.S. Hims & Hers HUGE Acquisition News!
• Positive Sentiment: Product/technology expansion — Hims is ramping AI‑driven preventive care (menopause, low testosterone, multi‑cancer testing and deeper personalization), which supports a higher‑value platform positioning longer term. Hims & Hers Accelerates AI Preventive Care and Platform Strategy
• Neutral Sentiment: Analysts flag mixed near‑term earnings implications — Some previews say platform strength and new specialties could help Q4 results, but recognize higher costs tied to deals and expansion may cloud near‑term profitability. Can Platform Strength Support Hims & Hers Stock Before Q4 Earnings?
• Negative Sentiment: Regulatory and legal scrutiny around GLP‑1/weight‑loss products — Coverage reports the company’s earlier GLP‑1/compounder strategy drew backlash from drugmakers and regulators, raising compliance, litigation and reputational risks that could hurt sales and margins. Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders
• Negative Sentiment: Reputational headlines and legal risk over “copycat” weight‑loss drugs — Media coverage and analysis highlight mounting criticism that could pressure demand or invite enforcement actions. Hims & Hers under fire over copycat weight loss drugs
• Neutral Sentiment: Deal financing and integration risk — Commentators note HIMS will use significant cash (and potentially other consideration) for the deal, raising questions about near‑term balance sheet flexibility and execution risk on integrating Eucalyptus. Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?

Hims & Hers Health Trading Down 1.2%

Shares of Hims & Hers Health stock opened at $15.62 on Friday. The firm has a 50-day simple moving average of $28.63 and a two-hundred day simple moving average of $40.35. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. Hims & Hers Health, Inc. has a fifty-two week low of $15.29 and a fifty-two week high of $70.43. The company has a market cap of $3.56 billion, a P/E ratio of 28.93, a price-to-earnings-growth ratio of 2.92 and a beta of 2.43.

Hims & Hers Health announced that its Board of Directors has initiated a stock buyback plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,090 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80. Following the transaction, the chief financial officer owned 94,333 shares in the company, valued at approximately $3,369,574.76. This represents a 19.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $308,767.81. Following the transaction, the insider directly owned 2,126 shares of the company’s stock, valued at approximately $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 82,963 shares of company stock worth $2,944,621 in the last ninety days. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.